IRIS
MARTINELLI, Erika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.808
NA - Nord America 8.018
AS - Asia 5.329
SA - Sud America 814
Continente sconosciuto - Info sul continente non disponibili 522
AF - Africa 73
OC - Oceania 21
Totale 27.585
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 8.155
US - Stati Uniti d'America 7.739
SG - Singapore 1.936
IE - Irlanda 1.253
IT - Italia 1.230
CN - Cina 1.075
HK - Hong Kong 835
BR - Brasile 659
VN - Vietnam 628
DE - Germania 469
GB - Regno Unito 464
UA - Ucraina 357
KR - Corea 301
FR - Francia 289
IN - India 151
FI - Finlandia 142
CA - Canada 133
SE - Svezia 118
GR - Grecia 106
TR - Turchia 102
JP - Giappone 90
AR - Argentina 59
NL - Olanda 45
BD - Bangladesh 44
PK - Pakistan 38
AT - Austria 37
MX - Messico 36
EC - Ecuador 30
CR - Costa Rica 25
IQ - Iraq 25
ID - Indonesia 24
PL - Polonia 22
BE - Belgio 21
HN - Honduras 18
LT - Lituania 17
ZA - Sudafrica 17
CZ - Repubblica Ceca 16
ES - Italia 16
GT - Guatemala 15
AU - Australia 14
CO - Colombia 14
MA - Marocco 14
CH - Svizzera 13
VE - Venezuela 13
TT - Trinidad e Tobago 12
CW - ???statistics.table.value.countryCode.CW??? 11
EE - Estonia 11
JM - Giamaica 10
CL - Cile 9
KE - Kenya 9
PY - Paraguay 9
BO - Bolivia 8
PE - Perù 8
SA - Arabia Saudita 8
IR - Iran 7
NZ - Nuova Zelanda 7
PH - Filippine 7
SV - El Salvador 7
TN - Tunisia 7
AZ - Azerbaigian 6
KG - Kirghizistan 6
PR - Porto Rico 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
DZ - Algeria 5
IL - Israele 5
JO - Giordania 5
NI - Nicaragua 5
SC - Seychelles 5
HU - Ungheria 4
NP - Nepal 4
SN - Senegal 4
UY - Uruguay 4
DO - Repubblica Dominicana 3
EG - Egitto 3
MK - Macedonia 3
MY - Malesia 3
RO - Romania 3
TH - Thailandia 3
AL - Albania 2
BB - Barbados 2
BG - Bulgaria 2
BY - Bielorussia 2
ET - Etiopia 2
EU - Europa 2
GA - Gabon 2
GI - Gibilterra 2
GP - Guadalupe 2
KZ - Kazakistan 2
LK - Sri Lanka 2
OM - Oman 2
RS - Serbia 2
TW - Taiwan 2
VG - Isole Vergini Britanniche 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
CG - Congo 1
CI - Costa d'Avorio 1
GE - Georgia 1
Totale 27.059
Salva come PNG Salva come JPEG
Città #
Moscow 2.983
Dublin 1.237
San Jose 1.062
Hong Kong 819
Singapore 811
Santa Clara 755
Ashburn 632
Chandler 607
Jacksonville 585
Council Bluffs 500
Seoul 276
Ho Chi Minh City 205
Beijing 197
Princeton 190
New York 168
Naples 156
Milan 152
Bremen 145
Roxbury 142
Dallas 141
Hanoi 141
Medford 131
Hefei 128
Los Angeles 110
Ann Arbor 106
Munich 105
The Dalles 84
Wilmington 80
Bengaluru 78
Caserta 76
São Paulo 71
Boardman 54
Chicago 50
Cambridge 46
Des Moines 43
San Mateo 41
Nanjing 39
Da Nang 36
Miano 36
Rome 36
Woodbridge 36
Haiphong 35
North Charleston 35
Napoli 32
Turku 32
Atlanta 31
Nuremberg 30
Tokyo 27
Houston 23
Orem 23
Amsterdam 22
Brasília 22
Brooklyn 22
Elora 22
Falkenstein 22
North Bergen 22
Vienna 22
Brussels 21
Montreal 21
Norwalk 21
Rio de Janeiro 21
Shanghai 21
Tianjin 21
Dong Ket 20
Frankfurt am Main 20
Helsinki 19
San José 19
Warsaw 18
Mountain View 17
Toronto 17
Bologna 16
Hải Dương 16
Las Vegas 16
Aversa 15
Columbus 15
Phoenix 15
Queens 15
Curitiba 14
Guangzhou 14
Nanchang 14
Belo Horizonte 13
Brno 13
Denver 13
Quito 13
Düsseldorf 12
Florence 12
London 12
Piscataway 12
San Francisco 12
Buffalo 11
Chennai 11
Istanbul 11
Jakarta 11
Manchester 11
Memphis 11
Ottawa 11
Willemstad 11
Changsha 10
Lappeenranta 10
Ninh Bình 10
Totale 14.348
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 262
Beyond N staging in colorectal cancer: Current approaches and future perspectives 239
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 222
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. 218
ONCOLOGIA MEDICA 216
AXL is an oncotarget in human colorectal cancer 206
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 203
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 202
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 200
Adjuvant chemoradiotherapy in patients with stage III-IV radically resected gastric cancer: a pilot study 196
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 195
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 191
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 190
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry 190
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 188
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 187
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 183
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 178
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 175
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 175
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 174
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial 173
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 173
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 172
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 172
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 171
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 171
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 171
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 169
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 169
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 169
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 168
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 168
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 167
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 166
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 163
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 163
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 161
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 161
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 161
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 161
The Role of Dual-Energy CT for the Assessment of Liver Metastasis Response to Treatment: Above the RECIST 1.1 Criteria 160
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 160
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 159
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 156
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 155
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 153
Correlation between efficacy and skin rash occurrence following treatment with the epidermal growth factor receptor inhibitor cetuximab: a single institution retrospective analysis 153
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 153
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 152
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 151
Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ 150
Pimasertib hydrochloride 150
Case report of unusual synchronous anal and rectal squamous cell carcinoma: clinical and therapeutic lesson 149
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 149
Farmacogenomica e cancro colorettale 149
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 149
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study 148
Light alcohol drinking and the risk of cancer development: a controversial relationship 148
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 147
Endoscopic calcium electroporation for unfit-for-surgery bleeding colorectal cancer: the dawn of a new treatment? 147
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 146
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 145
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 145
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 143
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 143
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 142
TRASTUZUMAB RESISTANCE IN BREAST CANCER 142
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 141
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 141
EGFR in Tumor-associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients. 141
Identification of perineural invasion at imaging staging as a novel potential risk factor in rectal cancer: A case report 140
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 140
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 139
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 139
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 138
Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer 138
Chemoradiotherapy as adjuvant treatment of gastric cancer 137
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 137
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)] 136
Prevention of cardiovascular complications in elderly cancer patients 135
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 135
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 135
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 134
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 134
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study 133
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 133
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 133
Capecitabine plus weekly oxaliplatin in gastrointestinal tumors. A phase I study 132
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 132
Targeting EGFR in Pancreatic Cancer Treatment. 132
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 132
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 132
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 132
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 132
Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. 131
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 131
Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator 130
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. 128
Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives 128
Totale 15.894
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.007
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 97.007
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.057 0 0 0 23 340 20 42 35 54 99 106 338
2022/20232.473 251 50 34 212 291 208 7 151 1.149 17 57 46
2023/2024992 93 37 38 51 335 140 19 24 11 14 74 156
2024/20253.318 56 105 54 107 471 432 339 320 471 448 268 247
2025/202614.012 559 606 669 682 1.097 7.587 705 749 606 374 238 140
2026/20272.849 137 451 1.085 1.176 0 0 0 0 0 0 0 0
Totale 27.585